Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Palbociclib + Anti-HER2 + Endo vs. Anti-HER2 + Endo Tafter Induct Tx for HR+/HER2-Pos Met Breast Can

Protocol: OSU-17311

Full Title

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

For More Information

See Full Trial at ClinicalTrials.gov
Email This Trial to Your Physician to Verify Eligibility
Print a Copy of This Trial
Learn More About Clinical Trial Phases
Protocol Page
Breast Cancer